<DOC>
	<DOCNO>NCT00571064</DOCNO>
	<brief_summary>This study determine effectiveness safety donepezil hydrochloride ( E2020 ) use treat resident assist live facility diagnose mild , moderate , severe stage Alzheimer 's disease .</brief_summary>
	<brief_title>The Effectiveness And Safety Of Donepezil Hydrochloride ( E2020 ) In Subjects With Mild To Severe Alzheimer 's Disease Residing In An Assisted Living Facility</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Age range : Subjects &gt; 50 year age . 2 . Sex distribution : men woman . Women must two ( 2 ) year postmenopausal surgically sterile . Women child bear potential ( &lt; 1 year post menopausal ) must practice effective contraception negative ßhCG screening ( Women breast feed exclude ) . 3 . MMSE score 5 24 ( inclusive ) . 4 . Subjects must diagnostic evidence possible probable AD either prior screen visit base Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) National Institute Neurological Communicative Disorders Stroke criterion . 5 . CT MRI within last 12 month consistent diagnosis AD without clinically significant comorbid pathology find . A copy report require collect . If significant change clinical status suggestive stroke neurological disease addition AD onset time last CT MRI screen evaluation , scan repeat screen . 6 . The caregiver/ informant family member professional must contact subject least 6 Weeks prior study entry spend minimum 3 day Week ( 10 hour per Week ) subject . For study visit , subject see Assisted Living Facility ( ALF ) clinic set Investigator . At visit , caregiver/informant provide information completion safety efficacy assessment base knowledge time spend subject . 7 . Subjects must reside ALF . 8 . The subject expect complete procedure schedule screening , baseline , interim , final visit include efficacy assessment . 9 . Putative nonprescription/prescription cognitive enhancer ( e.g . ginkgo , highdose vitamin E , lecithin , estrogen , nonsteroidal antiinflammatory drug [ NSAIDs ] ) exclude discourage . If putative cognitive enhancer present , dosage must stable least 3 month prior screen visit change course study . 10 . Subjects control hypertension ( sit diastolic BP &lt; 95 mmHg ) , right bundle branch block ( complete partial ) , pacemaker may include study . 11 . Subjects thyroid disease also may include study provide euthyroid stable treatment least 3 month prior screen . 12 . Subjects history seizure disorder allow provide stable treatment least 3 month prior screen seizure within past 6 month . 13 . Subjects must able swallow tablet medication crush tablet allow . 14 . Health : independent ambulatory aid ( i.e. , walker cane , wheelchair ) ; vision hearing ( eyeglasses and/or hearing aid permissible ) sufficient compliance test procedure . 15 . Subjects must sufficiently proficient language assessment conduct . 16 . Subjects must clinical laboratory value within normal limit , within Eisai ( sponsor ) guideline , abnormality consider clinically significant investigator sponsor . 1 . Age range : Subjects &lt; 50 year age . 2 . MMSE score ≤4 ≥25 . 3 . Subjects active clinically significant condition affect absorption , distribution metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer severe lactose intolerance ) . 4 . Subjects know hypersensitivity piperidine derivative cholinesterase inhibitor . 5 . Subjects live skilled nursing home subject live ALF may move skilled nursing home course study . Subjects transfer ALF skilled nursing home study discontinue . 6 . Subjects take follow medication within last 3 month prior screen eligible : Aricept , Exelon , Cognex , Razadyne , Metrifonate , Namenda propentofylline . 7 . Subjects without reliable caregiver/informant subject whose caregiver unwilling unable complete outcome measure fulfill requirement study . 8 . Subjects clinically significant obstructive pulmonary disease asthma , untreated &gt; 3 month . 9 . Subjects recent ( &lt; 2 year ) hematologic/ oncologic disorder , include mild anemia basal squamous cell carcinoma skin . Subjects current evidence malignant neoplasm recurrent metastatic disease exclude . 10 . Evidence clinically significant , active gastrointestinal , renal , hepatic , endocrine cardiovascular system disease . 11 . Subject current DSMlV diagnosis Major Depressive Disorder ( MDD ) current primary psychiatric diagnosis Alzheimer 's disease ( per DSMlV ) . 12 . Subjects dementia complicate organic disease ( DSM 290.30 290.11 ) exclude ; depression delusion common Alzheimer 's disease , subject severe symptom pronounce warrant alternative , concurrent diagnosis , exclude . 13 . Subjects know suspected history alcoholism drug abuse ( within past 10 year ) . 14 . Subjects treat hypothyroidism stable dose medication 3 month prior screen normal serum Free T3 , Free T4 TSH screen . 15 . Subjects treat vitamin B12 deficiency stable dose medication least 3 month prior study screen visit normal serum B12 level screen . 16 . Any subject taking prohibited medication exclude . 17 . Any condition would make subject caregiver , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>